Psoriatic Arthritis | Landscape & Forecast | Disease Landscape & Forecast

Publish date: June 2019

Login to access report

PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF inhibitors have revolutionized treatment of the disease and expanded the PsA therapy market to a multibillion-dollar entity. In recent years, several novel therapies with alternative MOAs, such as the IL-12/23 inhibitor ustekinumab, the oral PDE4 inhibitor apremilast, and the IL-17A inhibitor secukinumab, have entered this market and notably improved the outcome of patients who have an inadequate response to TNF inhibitors.

Three biologics and three oral agents are in late-stage development for PsA and are expected to launch during the 2017-2027 study period. Thought-leading physicians describe a dynamic patient-management environment with a growing need for additional novel therapies. In this content, we analyze physician perception and anticipated positioning of these agents and the implications for the market-leading TNF inhibitor class.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • June 2019
      • November 2018
      • August 2018
      • June 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for PsA?
        • What Factors Are Constraining the Market for PsA?
      • Drug-Class-Specific Trends
        • TNF Inhibitors
        • IL-12/23 Inhibitors
        • IL-17 Inhibitors
        • IL-23 Inhibitors
        • Selective Costimulation Modulators
        • PDE4 Inhibitors
        • JAK Inhibitors
        • cDMARDs
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
        • Pathogenesis
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
        • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases
        • Diagnosed Prevalent Cases of PsA
        • Drug-Treated Cases of PsA
    • Current Treatment Overview
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • TNF Inhibitors
        • IL-12/23 Inhibitors
        • PDE4 Inhibitors
        • IL-17 Inhibitors
        • JAK Inhibitors
        • Selective Costimulation Modulators
        • cDMARDs
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in PsA
    • Emerging Therapies Overview
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for PsA
        • JAK Inhibitors
        • IL-23 Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for PsA
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • PsA Bibliography

Author(s): Kristine Mackin, PhD; Arndt TJ

Kristine Mackin, is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.

joined Decision Resources Group in 2018 as an entry-level epidemiologist and previously worked in basic sciences research academia. earned his Masters in Public Health from the University of Florida, where he conducted an internship focused on developing a clinical model to non-invasively screen for Non-Alcoholic Steatohepatitis (NASH). He also holds a in Microbiology & Cell Science and a in Spanish, both from the University of Florida. During his undergraduate and graduate career, he worked in two physiology-based research labs at the University of Florida, focusing on maternal and fetal stresses during pregnancy and parturition.